This study developed and validated a BM-related risk score model (including DSG3, MET, and PLAU) in PC using multiple public and clinical cohorts, with a good prediction efficiency for the prognosis, tumor immune environment, and therapy response. This evidence concerns the gene DSG3 and pachyonychia congenita.